To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia (>3 mg/dL) during ALL induction therapy in adolescents and young adults (AYAs, age 15-39 years).

This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual BCG therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder cancer. The usual approach is defined as care most people get for bladder cancer.

The purpose of this research study is to explore the post-treatment barriers faced by adolescent and young adult (AYA) cancer survivors to therefore adapt the Needs Assessment and Service Bridge (NA-SB) tool produced by the UNC AYA Cancer Program. You are being asked to take part in a research study because you are an adolescent or young adult who has experienced cancer survivorship.